Research programme: parasitic infections therapeutics - Celgene Corporation/Drugs for Neglected Diseases Initiative Foundation

Drug Profile

Research programme: parasitic infections therapeutics - Celgene Corporation/Drugs for Neglected Diseases Initiative Foundation

Alternative Names: CGH VL series; Neglected tropical disease therapeutics

Latest Information Update: 20 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Celgene Corporation; Drugs for Neglected Diseases Initiative Foundation
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Elephantiasis; Leishmaniasis; Onchocerciasis; Trypanosomiasis
  • No development reported Chagas disease

Most Recent Events

  • 01 Aug 2016 Early research in Leishmaniasis is still ongoing in USA and Switzerland (DNDi pipeline, August 2016)
  • 16 Jul 2016 No recent reports of development identified for research development in Chagas'-disease in Switzerland
  • 16 Jul 2016 No recent reports of development identified for research development in Chagas'-disease in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top